SCHIELD study

Subcutaneous Contraceptive and HIV Implant Engineered for Long-Acting Delivery (SCHIELD) in Multipurpose Prevention Technology (MPT)

The study proposes to develop and test an innovative multipurpose prevention technology (MPT) in the form of a Subcutaneous Contraceptive and HIV Implant Engineered for Long-acting Delivery (SCHIELD).

The proposed innovative implant will offer a combination of attributes that surpass existing PrEP delivery systems: user-independence, biodegradation, long-term protection (up to 1 year), and discretion of use.

The study has three Specific Aims:

  • to develop a long acting MPT implant in the form of a subcutaneously inserted and biodegradable device that promotes adherence, acceptability, usage, and effectiveness over existing ARV and contraceptive delivery systems;

  • to test the safety and pharmacokinetics of the SCHIELD device to deliver ARV drugs and contraceptive hormones by completion of exploratory and IND-enabling preclinical studies; and

  • to conduct research activities necessary for technology optimization and for future implementation of the SCHIELD device into practice, including end-user (health providers and women) acceptability, implant deployment considerations, and applicator systems.

Funding Agent: USAID through RTI International Grant #: APS-OAA-16-000002
Collaborators and Partners: RTI International, PATH, UNC, UCSF, Gilead Sciences, University of Pittsburgh, Setshaba Research Centre and IRDO
Study Site(s): TBD (likely Kisumu)

2. -


Our Partners


CONTACT

Impact Research and Development Organization
Baring Road-Milimani
P.O. Box 9171-40141
Kisumu City
(254)-057-2020132
(254)-727-688550
(254)-738-772119
info@impact-rdo.org

Tu’ Washindi na PrEP

The Research

SCHIELD

Subcutaneous Contraceptive and HIV Implant Engineered for Long-Acting Delivery (SCHIELD) in Multipurpose Prevention Technology (MPT)

The study proposes to develop and test an innovative multipurpose prevention technology (MPT) in the form of a Subcutaneous Contraceptive and HIV Implant Engineered for Long-acting Delivery (SCHIELD).

The proposed innovative implant will offer a combination of attributes that surpass existing PrEP delivery systems: user-independence, biodegradation, long-term protection (up to 1 year), and discretion of use.

The study has three Specific Aims:

  • to develop a long acting MPT implant in the form of a subcutaneously inserted and biodegradable device that promotes adherence, acceptability, usage, and effectiveness over existing ARV and contraceptive delivery systems;

  • to test the safety and pharmacokinetics of the SCHIELD device to deliver ARV drugs and contraceptive hormones by completion of exploratory and IND-enabling preclinical studies; and

  • to conduct research activities necessary for technology optimization and for future implementation of the SCHIELD device into practice, including end-user (health providers and women) acceptability, implant deployment considerations, and applicator systems.

Funding Agent: USAID through RTI International Grant #: APS-OAA-16-000002
Collaborators and Partners: RTI International, PATH, UNC, UCSF, Gilead Sciences, University of Pittsburgh, Setshaba Research Centre and IRDO
Study Site(s): TBD (likely Kisumu)

Our Partners